AZN (AstraZeneca) Cyclically Adjusted Book per Share: $21.97 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AZN AstraZeneca PLC AZN
77 GF Score
Price $162.82
GF Value $182.70
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is AstraZeneca Cyclically Adjusted Book per Share?

AstraZeneca AZN -1.29% 77 Cyclically Adjusted Book per Share is $21.97 as of Jun. 2026. GuruFocus rates AZN with a GF Score™ of 77/100 and a GF Value™ of $182.70 (Modestly Undervalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

AstraZeneca's adjusted book value per share for the three months ended in Jun. 2026 was $32.430. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $21.97 for the trailing ten years ended in Jun. 2026.

During the past 12 months, AstraZeneca's average Cyclically Adjusted Book Growth Rate was 10.40% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 8.70% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 9.30% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 4.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of AstraZeneca was 12.50% per year. The lowest was -0.90% per year. And the median was 5.70% per year.

As of today (2026-08-20), AstraZeneca's current stock price is $162.82. AstraZeneca's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was $21.97. AstraZeneca's Cyclically Adjusted PB Ratio of today is 7.41.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of AstraZeneca was 10.10. The lowest was 4.21. And the median was 7.89.


AstraZeneca  (NYSE:AZN) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

AstraZeneca's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=162.82/21.97
=7.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of AstraZeneca was 10.10. The lowest was 4.21. And the median was 7.89.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


AstraZeneca Cyclically Adjusted Book per Share Related Terms


AstraZeneca Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for AstraZeneca's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca Cyclically Adjusted Book per Share Chart

AstraZeneca Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.06 14.60 16.40 17.44 19.65

AstraZeneca Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.21 20.17 19.65 21.25 21.97

AZN vs LLY, JNJ, ABBV: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - General subindustry, AstraZeneca's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Cyclically Adjusted PB Ratio falls into.


AZN
77GF Score
AstraZeneca PLC AZN
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AstraZeneca Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AstraZeneca's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=32.43/142.3000*142.3000
=32.430

Current CPI (Jun. 2026) = 142.3000.

AstraZeneca Quarterly Data

Book Value per Share CPI Adj_Book
201609 10.334 101.500 14.488
201612 11.740 102.200 16.346
201703 10.260 102.700 14.216
201706 10.786 103.500 14.829
201709 10.842 104.300 14.792
201712 11.815 105.000 16.012
201803 10.197 105.100 13.806
201806 9.983 105.900 13.414
201809 9.422 106.600 12.577
201812 9.840 107.100 13.074
201903 7.992 107.000 10.629
201906 10.328 107.900 13.621
201909 9.272 108.400 12.172
201912 10.004 108.500 13.120
202003 8.214 108.600 10.763
202006 9.325 108.800 12.196
202009 9.293 109.200 12.110
202012 11.901 109.400 15.480
202103 10.992 109.700 14.259
202106 11.941 111.400 15.253
202109 25.656 112.400 32.481
202112 25.344 114.700 31.442
202203 23.453 116.500 28.647
202206 23.190 120.500 27.385
202209 22.674 122.300 26.382
202212 23.898 125.300 27.140
202303 23.092 126.800 25.915
202306 24.126 129.400 26.531
202309 24.000 130.100 26.251
202312 25.251 130.500 27.534
202403 24.155 131.600 26.119
202406 25.487 133.000 27.269
202409 26.265 133.500 27.996
202412 26.312 135.100 27.714
202503 26.474 136.100 27.680
202506 28.847 138.400 29.660
202509 29.600 138.900 30.325
202512 31.383 139.900 31.921
202603 30.521 140.800 30.846
202606 32.430 142.300 32.430

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $21.97 mean?
AstraZeneca (AZN) has a Cyclically Adjusted Book per Share of $21.97 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on AstraZeneca and its competitors.
Is AstraZeneca's Cyclically Adjusted Book per Share too high?
AstraZeneca's current Cyclically Adjusted Book per Share is $21.97. Overall, AstraZeneca has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca's Cyclically Adjusted Book per Share compare to LLY and JNJ?
AstraZeneca's Cyclically Adjusted Book per Share of $21.97 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on AstraZeneca and its competitors. AstraZeneca's current Cyclically Adjusted Book per Share is $21.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca (AZN) is currently considered Modestly Undervalued. The stock's GF Value™ is $182.70, compared to a current price of $162.82 — trading 10.9% below its estimated fair value. The current Cyclically Adjusted Book per Share is $21.97. AstraZeneca's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For AstraZeneca (AZN), the current Cyclically Adjusted Book per Share is $21.97 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AstraZeneca (AZN) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be undervalued. The current stock price of $162.82 is trading 10.9% below its estimated GF Value™ of $182.70. GuruFocus considers AstraZeneca to be Modestly Undervalued.

Key valuation signals for AZN:

  • Cyclically Adjusted Book per Share: $21.97
  • GF Value™: $182.70 vs. price of $162.82 (10.9% below fair value)
  • GF Score™: 77/100 with 1 warning sign

No single metric tells the full story. See the AZN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
77GF Score

Get the complete analysis for AZN

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$162.82
Price
$182.70
GF Value